Table 1.
Baseline characteristics of the study subjects.
| SLE (n = 60) | HD (n = 31) | p-value | |
|---|---|---|---|
| Age, years | 41.4 ± 13.6 | 44.0 ± 19.3 | 0.8735 |
| Gender | M:F 5:55 | M:F 5:26 | 0.1366 |
| Disease duration, months | 142.3 ± 123.6 | ||
| Corticosteroid use | 40/60 | ||
| SLEDAI score | 11.5 ± 9.0 | ||
| BILAG score | 12.9 ± 11.0 | ||
| BILAG A1 and/or B2 | 36/60 | ||
| clinical relevant organ involvement (BILAG A or B) | |||
| constitutional | 24/60 (40.0%) | ||
| mucocutaneous | 26/60 (43.3%) | ||
| central nervous system | 14/60 (23.3%) | ||
| acute confusional state | 4 | ||
| cerebrovascular disease | 4 | ||
| seizure disorders | 2 | ||
| headache | 2 | ||
| mood disorder | 2 | ||
| cognitive dysfunction | 1 | ||
| aseptic meningitis | 1 | ||
| neuropathy, cranial | 1 | ||
| musculoskeletal | 10/60 (16.7%) | ||
| cardiovascular/respiratory | 2/60 (3.3%) | ||
| abdominal | 4/60 (6.7%) | ||
| renal | 20/60 (33.3%) | ||
| ophthalmic | 0/60 (0%) | ||
| haematological | 20/60 (33.3%) | ||
| anti-dsDNA Abs (IU/ml) | 76.6 ± 124.9 (55.0%) | ||
| anti-Sm Abs (U/ml) | 40.4 ± 137.2 (10.9%) | ||
| IgG (mg/dl) | 1,798 ± 606 | ||
| CH50 (U/ml) | 38.2 ± 17.2 | ||
| CRP (mg/dl) | 0.8 ± 1.9 | ||
| ESR (mm/h) | 47.2 ± 29.8 | ||
| WBC (/µl) | 4,727 ± 2,040 | ||
| Lymph (/µl) | 968 ± 668 | ||
| history of treatment | |||
| Immunosuppressants | 1.5 ± 1.6 | ||
| IVCY | 20 | ||
| AZ | 17 | ||
| TAC | 19 | ||
| CsA | 11 | ||
| MTX | 8 | ||
| MZ | 10 | ||
| RTX | 1 | ||
| HCQ | 7 | ||
| ABT | 3 | ||
| MMF | 1 | ||
| High-dose corticosteroid (times) | 0.8 ± 0.8 | ||
| Steroid pulse (times) | 0.5 ± 1.3 |
Data are mean ± SD or number of patients.
See Table 1 for abbreviations. IVCY, intravenous cyclophosphamide; AZ, azathioprine; TAC, tacrolimus; CsA, cyclosporin; MTX, methotrexate; MZR, mizoribine; RTX, rituximab; HCG, Hydroxychloroquine; ABT, abatacept; MMF, mycophenolate mofetil. High-dose corticosteroids were defined as the equivalent of prednisolone ≥0.8 mg/kg/day. Low-dose corticosteroids were defined as the equivalent of prednisolone ≤10 mg/day.